Ann: Bisantrene Phase 2 AML Trial Successful Concludes, page-51

I can only assume ASX11's point is that the other stock may be 'delisted' before that 12 month window for RAC is up. Hopefully, as I am a small holder from the 2 bucks days.

The only difficulty is, if you believe the other stock's prospects, it might be 2-3 times what it is now before delisting. (Maybe 4? I'm starting to get confused how 'platformy' the other stock is with this Alpha stuff in the works).

RAC's upside is more murky. I agree with others that $450 is pipe dream territory... but even the $30 chestnut everyone reckons is too low is 14 times from here. However whether that amount of upside is competing on the same 12 month timeline, I'm less sure.

I guess there is an argument that CPACS data ought to start rolling in assuming ethics/enrolment goes off without a hitch in the the next 6 months or so and we should in theory start getting healthy interest looking at how other stocks respond to such events. But the other stock has overcome inertia, we still need to get the snowball rolling from a somewhat standing start (ok, not completely, Dr T cornerstoned at 10c or whatever but we're still smallish market cap wise.)

As an aside I intensely get the sh*ts with some of the foam at the mouth "sell it all and buy RAC" posts that pop up from time to time. Find it grossly irresponsible. Even if you've got high hopes for RAC as many of us do, I find that sort of rabid up-ramping perversely switches on a bright orange caution light in my head despite my reading of announcements, Dr T's comms, research and the measured thoughts of other posters here. I am glad I'm not a new investor as while I likely would have still bought it would give me pause and I think it does this forum, and particularly beginner investors no favours.